NCT07491172RecruitingPhase 1
A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG17 sites in 4 countries90 target enrollmentStarted: June 21, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- CRISPR Therapeutics AG
- Enrollment
- 90
- Locations
- 17
- Primary Endpoint
- To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatments
Study Overview
Brief Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Detailed Description
This is a phase 1, open-label, multi-center study of CTX310 in participants with refractory dyslipidemias. Subjects will receive a dose of CTX310 via intravenous (IV) infusion.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age of ≥18 and ≤75 years at the time of signing the informed consent.
- •Able to provide written informed consent.
- •Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL in participants with or without ASCVD respectively, or TG ≥500 mg/dL.
- •Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening
- •Female participants must be postmenopausal or surgically sterile.
- •All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.
Exclusion Criteria
- •Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.
- •Evidence of liver disease, defined as but not limited to:
- •LFTS >2 × upper limit of normal (ULN), or total bilirubin >2 × ULN, or INR >1.5 × ULN, or liver stiffness measured by liver elastography
- •Abnormal or compromised function of kidney, heart, blood or liver.
- •Acute coronary syndrome event or stroke within 24 weeks prior to Day
- •Acute pancreatitis within 12 weeks prior to Day
- •Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).
- •Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.
- •Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).
- •Women of childbearing potential.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
- •Note: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.
Arms & Interventions
CTX310
Experimental
Subjects will receive an intravenous (IV) infusion.
Intervention: CTX310 (Drug)
Outcomes
Primary Outcomes
To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatments
Time Frame: From CTX310 infusion up to 12 months
Incidence of dose-limiting toxicities and frequency of adverse events
Secondary Outcomes
- To assess the preliminary efficacy of CTX310 in adult participants with dyslipidemias that are refractory to available treatments(Over 12 months, compared to baseline)
- To further characterize the safety of CTX310 in adult participants with dyslipidemias that are refractory to available treatments(From CTX310 infusion up to 12 months)
- To assess the pharmacokinetics (PK) of CTX310 in adult participants with dyslipidemias that are refractory to available treatments(From CTX310 infusion up to 12 months)
- To assess the pharmacodynamic (PD) response of CTX310 in adult participants with dyslipidemias that are refractory to available treatments(Over 12 months, compared to baseline)
Investigators
Study Sites (17)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsGastrointestinal CancerNCT07263594DualityBio Inc.127
Recruiting
Phase 1
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsSolid Metastatic TumorNCT07266298Neowise Biotechnology24
Recruiting
Phase 1
QLS5212 for Participants With Advanced Solid TumorsSolid Tumor CancerNCT07467629Qilu Pharmaceutical Co., Ltd.100
Recruiting
Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT07310134Nanjing Zenshine Pharmaceuticals80
Not yet recruiting
Phase 1
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid TumorAdvanced Solid TumorsNCT07327294Evopoint Biosciences Inc.150